<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354522</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-Breast-TCX</org_study_id>
    <nct_id>NCT01354522</nct_id>
  </id_info>
  <brief_title>TAC Versus TCX as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer</brief_title>
  <official_title>A Randomized, Phase III Study Comparing TAC (Docetaxel, Doxorubicin, Cyclophosphamide) With TCX ( Docetaxel, Cyclophosphamide, Capecitabine) as Adjuvant Treatment for Node-Positive Her2-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some sub-analysis has shown anthracycline-based regimens are not effective in Her-2 negative&#xD;
      breast cancer, while capecitabine is more effective in this group of patients.&#xD;
&#xD;
      This is a prospective, randomised phase III trial, to compare the efficacy and safety&#xD;
      profiles of two types of adjuvant chemotherapy regimens for HER2 negative, node positive&#xD;
      breast cancer patients.&#xD;
&#xD;
      Control Arm: This includes 6 cycles of TAC 75/50/500 mg/m2 day 1 every 3 weeks. Experimental&#xD;
      Arm: This includes 6 cycles of TC 75/500 mg/m2, day 1 every 3 weeks, concurrently with&#xD;
      capecitabine 950 mg/m2, twice a day, via oral intake, for 14 days, and then a one-week rest&#xD;
      period.&#xD;
&#xD;
      Women with hormone receptor positive tumours must receive 5 years endocrine after the end of&#xD;
      chemotherapy.&#xD;
&#xD;
      Patients may receive radiotherapy when clinically indicated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>3 years and 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate (CTCAE v. 3.0)</measure>
    <time_frame>3 years and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>TAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TCX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Doxorubicin, Cyclophosphamide</intervention_name>
    <description>docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles</description>
    <arm_group_label>TAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Cyclophosphamide, Capecitabine</intervention_name>
    <description>docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles</description>
    <arm_group_label>TCX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Histological diagnosis of operable invasive adenocarcinoma of the breast (T1-T3).&#xD;
             Tumours must be HER2 negative. Time window between surgery and study randomization&#xD;
             must be less than 60 days.&#xD;
&#xD;
          -  Surgery must consist of mastectomy or conservative surgery with axillary lymph node&#xD;
             dissection. Margins free of disease and ductal carcinomas in situ (DCIS) are required.&#xD;
             Lobular carcinoma is not considered a positive margin.&#xD;
&#xD;
          -  Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of&#xD;
             disease. If sentinel node technique is used, sentinel node can be the only node&#xD;
             affected.&#xD;
&#xD;
          -  Status of hormone receptors in primary tumour. Results must be available before the&#xD;
             end of adjuvant chemotherapy.&#xD;
&#xD;
          -  Patients must not present evidence of metastatic disease. Status of HER2 in primary&#xD;
             tumour, known before randomization. Patients with immune histochemistry (IHC) 0 or +1&#xD;
             are eligible. For patients with ICH 2+, fluorescence in situ hybridization (FISH) is&#xD;
             mandatory and result must be negative.&#xD;
&#xD;
          -  Age &gt;= 18 and &lt;= 70 years old.&#xD;
&#xD;
          -  Performance status (Karnofsky index) &gt;= 70.&#xD;
&#xD;
          -  Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed,&#xD;
             normal cardiac function must be confirmed by left ventricular ejection fraction&#xD;
             (LVEF).&#xD;
&#xD;
          -  Laboratory results (within 14 days prior to randomization):&#xD;
&#xD;
               -  Hematology: neutrophils &gt;= 1.5 x 10^9/l; platelets &gt;= 100 x 10^9/l; hemoglobin &gt;=&#xD;
                  10 mg/dl;&#xD;
&#xD;
               -  Hepatic function: total bilirubin &lt;= 1 upper normal limit (UNL); SGOT and SGPT &lt;=&#xD;
                  2.5 UNL; alkaline phosphatase &lt;= 2.5 UNL. If values of SGOT and SGPT &gt; 1.5 UNL&#xD;
                  are associated to alkaline phosphatase &gt; 2.5 UNL, patient is not eligible;&#xD;
&#xD;
               -  Renal function: creatinine &lt;= 175 mmol/l (2 mg/dl); creatinine clearance &gt;= 60&#xD;
                  ml/min;&#xD;
&#xD;
          -  Complete stage workup during the 12 weeks prior to randomization (mammograms are&#xD;
             allowed within a 20 week window). All patients must have a bilateral mammogram, thorax&#xD;
             x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or&#xD;
             alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is&#xD;
             recommended for all patients. Other tests: as clinically indicated.&#xD;
&#xD;
          -  Patients able to comply with treatment and study follow-up.&#xD;
&#xD;
          -  Negative pregnancy test done in the 14 prior days to randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior systemic therapy for breast cancer.&#xD;
&#xD;
          -  Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any&#xD;
             malignancy.&#xD;
&#xD;
          -  Prior radiotherapy for breast cancer.&#xD;
&#xD;
          -  Bilateral invasive breast cancer.&#xD;
&#xD;
          -  Pregnant or lactating women. Adequate contraceptive methods must be used during&#xD;
             chemotherapy and hormone therapy treatments.&#xD;
&#xD;
          -  Any T4 or M1 tumour.&#xD;
&#xD;
          -  HER2 positive breast cancer (IHC 3+ or positive FISH result).&#xD;
&#xD;
          -  Pre-existing grade &gt;= 2 motor or sensorial neurotoxicity (National Cancer Institute&#xD;
             Common Toxicity Criteria version 2.0 [NCI CTC v-2.0]).&#xD;
&#xD;
          -  Any other serious medical pathology, such as congestive heart failure; unstable&#xD;
             angina; history of myocardial infarction during the previous year; uncontrolled HA or&#xD;
             high risk arrhythmias.&#xD;
&#xD;
          -  History of neurological or psychiatric disorders, which could preclude the patients&#xD;
             from free informed consent.&#xD;
&#xD;
          -  Active uncontrolled infection.&#xD;
&#xD;
          -  Active peptic ulcer; unstable diabetes mellitus.&#xD;
&#xD;
          -  Previous or current history of neoplasms different from breast cancer, except for skin&#xD;
             carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and&#xD;
             without recurrence in the last 10 years; ductal in situ carcinoma in the same breast;&#xD;
             lobular in situ carcinoma.&#xD;
&#xD;
          -  Chronic treatment with corticosteroids.&#xD;
&#xD;
          -  Contraindications for corticosteroid administration.&#xD;
&#xD;
          -  Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor&#xD;
             modulators (SERMs), either for osteoporosis treatment or for prevention. These&#xD;
             treatments must stop before randomisation.&#xD;
&#xD;
          -  Concomitant treatment with other investigational products; participation in other&#xD;
             clinical trials with a non-marketed drug in the 20 previous days before randomization.&#xD;
&#xD;
          -  Concomitant treatment with another therapy for cancer.&#xD;
&#xD;
          -  Males.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Sun, Master</last_name>
    <role>Study Chair</role>
    <affiliation>PUMCH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Sun, Master</last_name>
    <phone>86-010-88068936</phone>
    <email>sunq@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Songjie Shen, Doctor</last_name>
    <phone>86-010-88068936</phone>
    <email>pumcssj@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Sun, Master</last_name>
      <phone>86-010-88068936</phone>
      <email>sunq@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Songjie Shen, Doctor</last_name>
      <phone>86-010-88068936</phone>
      <email>pumcssj@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Qiang Sun, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

